Company intelligence / Profile preview
ZyVersa Therapeutics
Weston, Florida, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead clinical program (VAR 200) is a cholesterol transport mediator for rare kidney diseases, with a novel inflammasome inhibitor (IC 100) in-licensed for inflammatory and autoimmune diseases in preclinical/early clinical development. Both address high unmet needs in orphan and inflammatory disease markets.
- Therapeutic areas
- ImmunologyNeurologyNephrologyGastroenterology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
InflamaCORE, LLC (licensing partner for IC 100)
Beyond the preview
Go deeper on ZyVersa Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZyVersa Therapeutics.